pharmaphorum

OCTOBER 18, 2024

Sanofi invests €300m in Orano Med's lead-based radioligandsSanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear fuel company Orano.The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT) for rare neuroendocrine tumours (NETs) c

Fierce Pharma

OCTOBER 18, 2024

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer med Vyloy. | Astellas' Vyloy won an FDA approval to treat gastric or gastroesophageal junction adenocarcinoma patients whose tumors are CLDN18.2 positive. The drug was rejected earlier this year thanks to observations raised during the agency's inspection of a third-party manufacturing facility.

FDA

Drug Topics

OCTOBER 18, 2024

Acupuncture, a practice with thousands of years of history, has become increasingly accepted in mainstream medicine.

PharmaVoice

OCTOBER 18, 2024

From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

OCTOBER 18, 2024

Research is limited on the effectiveness and efficacy of this class of medications.

STAT

OCTOBER 18, 2024

Pascal Geldsetzer believes in open access, in disseminating science as quickly as it happens. Even so, last summer, as he uploaded the surprising results of his latest study to the MedRxiv preprint server, the Stanford University epidemiologist was feeling something other than the usual excitement. “I was scared to put this up because it’s such a different approach from what’s generally done in epidemiology and medicine,” he said.

Pharmacy Times

OCTOBER 18, 2024

The additions include Dextrose 70% intravenous (IV) solution, Lactated Ringers IV Solution, and Peritoneal Dialysis Solution, which were affected by Hurricane Helene.

FDA

Drug Topics

OCTOBER 18, 2024

Patients with chronic migraine can frequently overuse acute medications, leading to medication overuse headaches.

STAT

OCTOBER 18, 2024

Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $63 billion in 2023, a 23.4% increase from the previous year, according to the Health Resources & Services Administration, which oversees the program. The data mark a steady rise in sales under the 340B Drug Discount Program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — off all outpatient drugs to hospit

Hospitals

Drug Topics

OCTOBER 18, 2024

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

OCTOBER 18, 2024

Zolbetuximab is the first approved CLDN18.2-targeted treatment for gastric and gastroesophageal junction adenocarcinoma.

FDA

Drug Topics

OCTOBER 18, 2024

David Pope, PharmD, Chief Pharmacy Officer at XiFin, joined Drug Topics to discuss value-based care and how it has changed the way pharmacy operates.

STAT

OCTOBER 18, 2024

WASHINGTON — Californians are about to vote on an aggressive policy proposals to reform a drug discount program that is a key source of revenue for hospitals and health clinics. The group behind it? Apartment builders.  As a general rule, programs named after the sub-section of the law in which they were created are not well-known. The 340B Drug Discount Program is no exception.

Hospitals

Pharmacy Times

OCTOBER 18, 2024

Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

OCTOBER 18, 2024

As a child in Jacksonville, Fla., Alex Chern built string instruments out of office supplies and tuned them, stretching rubber bands taut to change their pitch. Starting at age 7, he took violin lessons and continued playing all the way through college at Yale University. He loved playing Beethoven, expressive pieces written in F major like “Romance No. 2” or the “Spring Sonata,” and technically challenging pieces like Bach’s “Sonatas and Partitas,ȁ

Medical Schools

Fierce Pharma

OCTOBER 18, 2024

As recovery efforts at the North Carolina plant hit by Hurricane Helene move at an “encouraging pace,” Baxter International is laying out new details on a sweeping importation plan to help critical | Baxter has said the first IV product shipments cleared by the FDA for temporary importation are set to arrive in the U.S. this weekend. By the end of the year, the company expects nearly 18,000 tons of product from Europe and Asia to reach The States.

FDA

Fierce Healthcare

OCTOBER 18, 2024

It's a tumultuous time at industry giant CVS Health, and on Friday the company revealed a shake-up at the top that now has David Joyner stepping in as CEO. | It's a tumultuous time at industry giant CVS Health, and on Friday the company revealed a shake-up at the top that now has David Joyner stepping in as CEO.

Fierce Pharma

OCTOBER 18, 2024

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. | After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S.

FDA

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

OCTOBER 18, 2024

The HLTH 2024 conference will kick off Sunday in Las Vegas with an expected 12,000 attendees from across the industry to plot the future of healthcare innovation. | The HLTH 2024 conference will kick off Sunday in Las Vegas with an expected 12,000 attendees from across the industry to plot the future of healthcare innovation.

STAT

OCTOBER 18, 2024

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Good morning! For those who were wise enough to attend, hope you enjoyed this year’s STAT Summit. Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more.

Pharmacy Times

OCTOBER 18, 2024

Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.

STAT

OCTOBER 18, 2024

CVS Health has replaced Karen Lynch with David Joyner as CEO, it said Friday, part of an attempt to turn the struggling company around.  Joyner was previously the president of CVS Caremark, the company’s pharmacy benefit manager, and formerly worked at Aetna, the insurer now owned by CVS. The company said Lynch had stepped down “in agreement” with the company’s board.

Insurance

Fierce Pharma

OCTOBER 18, 2024

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan, chair of the U.S. Federal Trade Commission, urging the antitrust agency to block Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent.

STAT

OCTOBER 18, 2024

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. I’m recovering from the STAT Summit — in particular, recovering from this stunning view of Boston from the venue. On Wednesday evening, we had an amazing view of the almost-supermoon rising as dusk settled in during the last panel of the day.

pharmaphorum

OCTOBER 18, 2024

Jörg Möller's sojourn as CEO of BenevolentAI has come to an abrupt end, as the firm names co-founder Ken Mulvany as executive chair

STAT

OCTOBER 18, 2024

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You can also read Eli Lilly chief scientist Daniel M. Skovronsky on fallacies surrounding patents, drug discovery, and affordability,   Sandoz CEO Richard Saynor  on what the 2024 conversation is missin

Pharmaceutical Companies

pharmaphorum

OCTOBER 18, 2024

AbbVie has finally claimed FDA approval for its 24-hour Parkinson's therapy Vyalev, 18 months after the US regulator turned it down

FDA

STAT

OCTOBER 18, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

pharmaphorum

OCTOBER 18, 2024

MSD reveals the data that could unlock filings for clesrovimab, a rival to Sanofi and AstraZeneca's Beyfortus for preventing infant RSV infections

Fierce Pharma

OCTOBER 18, 2024

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment concizumab. | Novo Nordisk received good news from European drug reviewers on its hemophilia treatment, while PTC Therapeutics' Duchenne Muscular Dystrophy therapy was again recommended for rejection upon a re-examination.

FDA

Pharmaceutical Technology

OCTOBER 18, 2024

Late-stage pipeline products could drive combined sales of approximately $171.4 million by 2033 in the 8MM.

The Guardian - Pharmaceutical Industry

OCTOBER 18, 2024

Scientists say using the drugs to get people back into work could carry logistical and ethical problems Weight loss jabs are not a “quick fix” and the health secretary’s plan to use them to help people get back to work could backfire, experts have warned. Wes Streeting announced a real-world trial of the medication’s impact on worklessness this week, saying that “widening waistbands” were placing a burden on the NHS.

The Checkup by Singlecare

OCTOBER 18, 2024

You may have just popped a Nurtec ODT pill, ready to sip on some wine and relax after a long day. Suddenly, it hits you: “Can I even mix these two?” That moment of panic is all too familiar for many. Nurtec is a prescription drug that is FDA approved for managing migraine attacks and preventing episodic migraine, but it might not always pair with an evening drink.

Compounding